Teva Emerges From Restructuring Ready To Grow

Captures 12%-15% Rituximab Share In US With Truxima Biosimilar

Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.

Butterfly
Teva has emerged from years of restructuring ready to grow • Source: Shutterstock

Teva says the completion of its restructuring plan has put the firm in a position to increase its turnover through sales of newly-launched products – including biosimilars, brands and new generic launches – as well as to improve its profit margins through continued optimization of its manufacturing operations.

The Israeli company saw its overall sales drop by 8% to $16.887bn in 2019 – translating to a 5% constant-currency...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Byooviz US Launch Slated For 2026 As Harrow Touts Immediate Uptake Potential

 
• By 

Harrow is taking aim at launching new partner Samsung Bioepis’ Byooviz biosimilar to Lucentis in 2026.

Fresenius Kabi Pharma Bounces Back In Q2 With Strong US and Europe Volumes

 
• By 

Fresenius Kabi’s IV drugs and fluids Pharma division rebounded in Q2, led by strong US and European volumes, especially in infusion therapies. Biopharma revenue rose by 26% to €190m, up one-third in constant currencies, driven by tocilizumab biosimilar ramp-up in Europe and the US.

Richter Sets Launch Timetable for Denosumab and Tocilizumab Biosimilars

 
• By 

Gedeon Richter’s management discussed timelines for two key biosimilars during the firm’s first-half earnings call, while also revealing how the firm’s General Medicines division had suffered setbacks in the three months to June 30.

Viatris Signals Ongoing Strategic Overhaul, Promises Update In Q3

 
• By 

Viatris is conducting a company-wide strategic review to boost long-term competitiveness, targeting cost savings and a shift to complex, high-margin products. CEO Scott Smith says it’s timely after four divestitures. An update is due in the Q3 2025 earnings call in November.

More from Business

Viatris Signals Ongoing Strategic Overhaul, Promises Update In Q3

 
• By 

Viatris is conducting a company-wide strategic review to boost long-term competitiveness, targeting cost savings and a shift to complex, high-margin products. CEO Scott Smith says it’s timely after four divestitures. An update is due in the Q3 2025 earnings call in November.

Lupin Couples Up With Sandoz For Global Lucentis Biosimilar Deal

 

Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.

Hikma Rides Price Gap as Novo’s Ozempic, Wegovy Costs Climb

 
• By 

Hikma is seeing increased US demand for its generic Victoza (liraglutide) after the end of semaglutide compounding lifted prices for Novo Nordisk’s Ozempic and Wegovy. Meanwhile, the company is not for now pursuing semaglutide generics in the US or EU due to patent protection, but is targeting MENA.